Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1147 ARTÍCULOS , VIENDO DEL 166 AL 180

The secretases: enzymes with therapeutic potential in Alzheimer disease

De Strooper B, Vassar R, Golde T.

Nat Rev Neurol. 2010 Feb;6(2):99-107. doi: 10.1038/nrneurol.2009.218.

Can Alzheimer disease be prevented by amyloid-beta immunotherapy?

Lemere CA, Masliah E.

Nat Rev Neurol. 2010 Feb;6(2):108-19. doi: 10.1038/nrneurol.2009.219.

3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI

Apostolova LG, Thompson PM, Green AE, Hwang KS, Zoumalan C, Jack CR Jr, Harvey DJ, Petersen RC, Thal LJ, Aisen PS, Toga AW, Cummings JL, Decarli CS.

Hum Brain Mapp. 2010 May;31(5):786-97. doi: 10.1002/hbm.20905.

Attention network functioning in patients with dementia with Lewy bodies and Alzheimer's disease

Fuentes LJ, Fernández PJ, Campoy G, Antequera MM, García-Sevilla J, Antúnez C.

Dement Geriatr Cogn Disord. 2010;29(2):139-45. doi: 10.1159/000275672. Epub 2010 Feb 10.

Assessment and familial aggregation of psychosis in Alzheimer's disease from the National Institute on Aging Late Onset Alzheimer's Disease Family Study

Sweet RA, Bennett DA, Graff-Radford NR, Mayeux R; National Institute on Aging Late-Onset Alzheimer's Disease Family Study Group.

Brain. 2010 Apr;133(Pt 4):1155-62. doi: 10.1093/brain/awq001. Epub 2010 Feb 10.

A qualitative assessment of the concept of dependence in Alzheimer's disease

Frank L, Howard K, Jones R, Lacey L, Leibman C, Lleo A, Mannix S, Mucha L, McLaughlin T, Zarit S.

Am J Alzheimers Dis Other Demen. 2010 May;25(3):239-47. doi: 10.1177/1533317509356690. Epub 2010 Feb 10.

Tau protein and tau aggregation inhibitors

Bulic B, Pickhardt M, Mandelkow EM, Mandelkow E.

Neuropharmacology. 2010 Sep-Oct;59(4-5):276-89. doi: 10.1016/j.neuropharm.2010.01.016. Epub 2010 Feb 10.

[BAC 40 battery: a tool of cognitive evaluation for the diagnosis of Alzheimer's disease at the specialist office]

Guard O.

Rev Neurol (Paris). 2010 Jun-Jul;166(6-7):615-20. doi: 10.1016/j.neurol.2010.01.001. Epub 2010 Feb 10.

Using qualitative methods to inform the trade-off between content validity and consistency in utility assessment: the example of type 2 diabetes and Alzheimer's disease

McGrath C, Rofail D, Gargon E, Abetz L.

Health Qual Life Outcomes. 2010 Feb 12;8:23. doi: 10.1186/1477-7525-8-23.

Neuroimmunomodulatory steroids in Alzheimer dementia

Hampl R, Bicíková M.

J Steroid Biochem Mol Biol. 2010 Apr;119(3-5):97-104. doi: 10.1016/j.jsbmb.2010.02.007. Epub 2010 Feb 11.

Troubleshooting methods for APP processing in vitro

Sastre M.

J Pharmacol Toxicol Methods. 2010 Mar-Apr;61(2):86-91. doi: 10.1016/j.vascn.2010.02.003. Epub 2010 Feb 12.

The role and therapeutic potential of monocytic cells in Alzheimer's disease

Malm T, Koistinaho M, Muona A, Magga J, Koistinaho J.

Glia. 2010 Jun;58(8):889-900. doi: 10.1002/glia.20973.

Shape analysis of the neostriatum in frontotemporal lobar degeneration, Alzheimer's disease, and controls

Looi JC, Walterfang M, Styner M, Svensson L, Lindberg O, Ostberg P, Botes L, Orndahl E, Chua P, Kumar R, Velakoulis D, Wahlund LO.

Neuroimage. 2010 Jul 1;51(3):970-86. doi: 10.1016/j.neuroimage.2010.02.017. Epub 2010 Feb 13.

Multi-center study on Alzheimer's disease using FDG PET: group and individual analyses

Yuan X, Shan B, Ma Y, Tian J, Jiang K, Cao Q, Wang R.

J Alzheimers Dis. 2010;19(3):927-35. doi: 10.3233/JAD-2010-1287.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias